Genetic methods identify and prioritize drug targets in major depressive disorder, suggesting new repurposing strategies.
Key Points
Drug targets identified through genetic methods showed a significant association with major depressive disorder, leading to innovative treatment strategies.
Using genome-wide association study data from over 525,000 cases, the research evaluates over 3,469 druggable targets for MDD.
Cis-Mendelian randomisation was employed to strengthen causal inference, revealing that 82% of approved depression drugs had significant genetic targets.
The findings indicate novel mechanisms beyond traditional antidepressants, suggesting immediate repurposing opportunities for existing drugs.